NCT04856787 2025-05-18
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Terminated
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ruijin Hospital
University of Wisconsin, Madison
Auron Healthcare GmbH